Cargando…
Thromboxane A2 receptor (TBXA2R) is a potent survival factor for triple negative breast cancers (TNBCs)
Triple Negative Breast Cancer (TNBC) is defined by the lack of ERα, PR expression and HER2 overexpression and is the breast cancer subtype with the poorest clinical outcomes. Our aim was to identify genes driving TNBC proliferation and/or survival which could represent novel therapeutic targets. We...
Autores principales: | Orr, Katy, Buckley, Niamh E., Haddock, Paula, James, Colin, Parent, Jean-Luc, McQuaid, Stephen, Mullan, Paul B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342429/ https://www.ncbi.nlm.nih.gov/pubmed/27487152 http://dx.doi.org/10.18632/oncotarget.10969 |
Ejemplares similares
-
Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer
por: Watkins, Gareth, et al.
Publicado: (2005) -
Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer
por: Knowlson, Catherine, et al.
Publicado: (2020) -
NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
por: Mullan, Paul B., et al.
Publicado: (2019) -
Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer
por: Elkashif, Ahmed, et al.
Publicado: (2020) -
A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer
por: Buckley, Niamh E., et al.
Publicado: (2016)